After the close on Friday, 10/15/10, Allergan, Inc. AGN announced that the FDA approved Botox for chronic migraine (CM), Wells Fargo reports, noting that the approval came a few weeks sooner than we expected.
“We view this news very positively because we believe the CM indication will contribute about $500MM in incremental sales to AGN by 2014 and will increase AGN's 2010-2014 sales CAGR by 200bps (6.8% vs 4.8%),” Wells Fargo writes.
“The CM indication will very likely augment AGN's EPS growth by a greater degree given the low level of incremental investment needed to drive CM sales because AGN is already promoting Botox to neurologists for other indications.”
Allergan currently trades for $71.88.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in